Rich page
Centre pluridisciplinaire ambulatoire spécialisé TCA
Image Un centre spécialisé dans les Troubles du Comportement Alimentaire (TCA)Notre centre se distingue par une approche pluridisciplinaire et individualisée, alliant détection précoce, orientation ciblée et soins spécialisés.Nous adoptons une approche globale qui combine des thérapies individuelles, familiales et de groupe. Nous intégrons des méthodes reconnues telles que la Family Based Therapy (FBT) et, prochainement, la Multi Familial Therapy (MFT), tout en offrant des soins diététiques et corporels adaptés.En cas de besoin, une prise en charge intensive peut être proposée.Notre objectif : accompagner patients et familles vers un rétablissement durable grâce à un parcours de soins structuré et coordonné.Fiche santé TCA A Erasme, la prise en charge des TCA s’adresse aux jeunes de 12 à 23 ans présentant des troubles tels que l’anorexie, la boulimie ou l’hyperphagie boulimique.A l’Hôpital des Enfants (HUDERF), la prise en charge des TCA s’adresse aux enfants et adolescents jusque 15 ans, présentant des troubles tels que l’ARFID/trouble alimentaire pédiatrique, l’anorexie, la boulimie ou l’hyperphagie boulimique.%20cpij [dot] psychiatrie [dot] erasme [at] hubruxelles [dot] be (Envoyer un mail)  De manière générale nos consultations s'adressent aux :familles souhaitant un accompagnement global, intégrant les proches comme acteurs clés de la guérison.patients nécessitant une prise en charge personnalisée, adaptée à leurs besoins psychiques et physiques. Nos expertes Pr. Veronique Delvenne, Directrice du service de psychiatrie du bébé, de l’enfant, de l’adolescent et du jeune adulte (H.U.B)Véronique Delvenne, professeure de psychiatrie de l’enfant et de l’adolescent à l’Université libre de Bruxelles (ULB), est une spécialiste reconnue en pédopsychiatrie en Belgique.Membre de l’Académie royale de Médecine de Belgique, elle a concentré ses travaux sur les troubles des conduites alimentaires et sur les enjeux spécifiques de la psychiatrie en âge de transition. Par son expertise et ses recherches, elle contribue à faire évoluer les connaissances et les pratiques dans ces domaines essentiels de la santé mentale. Dr Judith Dereau,  Pédopsychiatre référente de la prise en charge des TCA à l'H.U.BLe Dr Judith Dereau, responsable médicale du Centre ambulatoire TCA de l’H.U.B., s’impose comme une figure incontournable dans le paysage belge francophone des professionnels spécialisés dans les TCA. Experte reconnue, elle partage son expérience et ses connaissances à travers l’animation de séminaires et des interventions régulières lors de congrès.Forte d’une pratique clinique hospitalière et ambulatoire développée depuis 2003, le Dr Dereau met son expérience au service de la formation et de l’innovation des prises en charge. Notre équipe Pédopsychiatres Dr Mouna Al-Husni (HUDERF-Erasme)Pr Véronique Delvenne (HUDERF)Dr Judith Dereau (Erasme)Dr Maria Talib (HUDERF-Erasme) Au niveau somatiqueDr Jean-Charles Preiser (Erasme)Dr Celine Roman PsychologuesMme Christella di FioreMme Silvana Fuso (HUDERF-Erasme)Mme Nadia Ramsis KinésithérapeutesMme Nora El Meziani DiététiciensMme Charlotte Dupont Erasme Medical Center (EMC) Route de Lennik 900 − 1070 Bruxelles Standard EMC +32 (0)2 555 31 11 Secrétariat Pédopsychiatrie +32 (0)2 555 32 96Prendre rendez-vous  Hôpital des Enfants (Huderf) Avenue Jean Joseph Crocq 15 - 1020 BruxellesSecrétariat Pédopsychiatrie: +32 2 477 31 80Prendre Rendez-vous  Service de Psychiatrie du bébé, de l'enfant, de l'adolescent et du jeune adulte
Article
When the liver is diseased, why can the kidneys also be affected?
An international study to which the H.U.B contributed sheds new light on a severe complication of decompensated cirrhosis: kidney impairment. The researchers discovered that a variation in our genetic make-up could help explain the pathophysiological mechanisms underlying its occurrence. Image The liver and kidneys have very different functions. However, when the liver is severely affected, the kidneys may also become compromised. This is particularly the case in decompensated cirrhosis, meaning that the liver disease has reached a stage at which complications develop. At this advanced stage of liver disease, the kidneys remain particularly vulnerable to functional impairment. This kidney injury is a serious complication that can sometimes develop rapidly and worsen the prognosis.But one question remains difficult to explain: why do some patients develop kidney injury while others, despite having comparable liver disease, do not? A new international study, published in The Lancet Gastroenterology & Hepatology, provides an initial answer: our genetic make-up may play a role.Searching for a difference in our DNATo conduct this research, the scientists studied the genetic make-up of thousands of people with cirrhosis. The main study included 3,220 South American and European patients with decompensated cirrhosis. The researchers then validated their observations in 1,728 additional patients from several independent cohorts. They also compared their results with those of people with compensated cirrhosis and with those of more than 400,000 people from the general population without cirrhosis. The aim was to identify variations in DNA that might be associated with blood creatinine, a marker used to assess kidney function.The researchers identified a common genetic variation located in a region of the genome containing the SUSD1 gene. This variation was associated with higher creatinine levels and a higher frequency of kidney failure in people with decompensated cirrhosis. In patients carrying two copies of the variant considered to be at risk, the risk of kidney failure was approximately 60% higher than in those carrying two copies of the other version of the variant.This result does not mean that a gene “condemns” the kidneysIt is important to understand clearly that this common genetic variation does not mean that a patient will necessarily develop kidney injury. An individual’s susceptibility to kidney injury depends on many factors, such as the severity of the liver disease, any other medical conditions, infections and medications. Genetics is one factor among many.Another important observation is that the association between this genetic variation and kidney function was not observed in patients with compensated cirrhosis or in the general population. This therefore suggests that the effect of this genetic variation manifests itself in the context of an already severely diseased liverWhat happens between the liver and the kidney?The study also provides a lead for understanding this phenomenon. The researchers studied cells present in different tissues in order to assess the pathophysiological mechanisms linking SUSD1 to impaired kidney function. In particular, they identified the potential contribution of immune-system cells known as plasmacytoid dendritic cells. In patients whose kidneys were affected, these cells were more numerous, and certain communication pathways involving type I interferons—molecules produced notably during immune responses—were more active in the liver and kidneys. These results suggest that an immune-system reaction may contribute to the link between liver failure and kidney injury.However, precisely how this reaction is triggered and the exact role played by the SUSD1 gene remain to be understood. The researchers therefore describe this as a biological lead that still requires further study.“Our aim is to better understand why the kidneys become particularly vulnerable in some patients with decompensated cirrhosis. This study highlights a genetic component and an immune pathway that deserve further investigation. At this stage, it mainly provides insight into the possible mechanisms of the disease; it does not yet make it possible to predict a patient’s course or select their treatment,” explains Professor Éric Trépo, hepatologist at H.U.B. and F.R.S.-FNRS Research Associate.Why is this discovery important for patients?Because it helps improve our understanding of the biological mechanisms that may contribute to kidney injury, a complication that can be particularly difficult to manage.This study suggests that part of this difference could be linked to patients’ own biology, including their genetic make-up. In the long term, better identification of particularly vulnerable patients could make it possible to further tailor their monitoring and care. The longer-term aim would be to identify situations at risk earlier and, if new therapeutic targets are confirmed, to develop treatments that act more precisely on the mechanisms responsible for kidney injury.A pathway towards more personalised medicineHowever, we are still at the beginning of this journey. This discovery does not mean that a genetic test capable of predicting kidney injury will soon be offered to all patients with cirrhosis. The predictive value of this association and its clinical usefulness still need to be assessed in prospective studies. But these results open up a new avenue of research: gaining a better understanding of the individual susceptibility of the patients concerned.For people living with decompensated cirrhosis, this research could therefore ultimately contribute to more personalised care, if its clinical usefulness is demonstrated. This is one of the current challenges in hepatology research: gradually moving from medicine that treats complications when they occur to medicine capable of better anticipating each patient’s individual course.This research project is supported by the Erasme Fund. Read the scientific publication Read the EF CLIF press release Our researchers Dr Eric Trépo, Hepatologist at H.U.B and Research Associate of the F.R.S.-FNRS.Dr Lukas Otero Sanchez, Resident in Gastroenterology at H.U.B, Candidate Specialist Trainee – Erasmus Fund Researcher Learn more about our researchers’ projects Projects supported by the Erasmus Fund. Research projects of Dr Eric Trépo Research projects of Dr Otero Sanchez  Learn more about our Gastroenterology and Hepato-pancreatology DepartmentFor comprehensive care of digestive disordersThe Gastroenterology and Hepato-pancreatology Department at H.U.B-Erasmus provides comprehensive care for digestive disorders within a leading university hospital. Our mission is based on three fundamental pillars: the highest quality of care, the transmission of knowledge through teaching, and continuous innovation through research. Discover our department
Health issues
Congenital hypothyroidism
Department overview The Adult Endocrinology Clinic provides diagnosis and follow-up for adult patients with an endocrine problem, that is, a condition affecting the secretion of a hormone (excessive or insufficient secretion) and/or the gland that secretes it. The department therefore manages conditions affecting the thyroid, parathyroid glands, adrenal glands, gonads (ovaries and testicles), and pituitary gland. Since 2016, the Endocrinology Department of Erasme Hospital, in association with the Queen Fabiola Children’s University Hospital (HUDERF) for paediatric care, has been part of ENDO-ERN (European Reference Network for Rare Endocrine Conditions), the European Reference Network for rare endocrine diseases.This network aims to improve access to high-quality care for patients with rare endocrine disorders. It supports clinical research and contributes to the creation of registries listing patients receiving follow-up for rare conditions, in order to promote knowledge sharing and improve clinical practice. The management of rare endocrine diseases is multidisciplinary. Regular consultations are organised to discuss complex cases, with numerous specialists within our institution, as well as during virtual consultations with recognised European experts through the ENDO-ERN network or during international multidisciplinary case meetings (France).Some endocrine diseases begin at birth or during childhood and require lifelong treatment and follow-up. Transition consultations have been provided for many years with our paediatric colleagues at HUDERF to ensure the smoothest possible transition from paediatric to adult care. What are rare congenital thyroid diseases? Rare congenital thyroid diseases are conditions that are most often present from birth and affect the functioning of the thyroid gland. In most cases, they are congenital hypothyroidism, meaning insufficient production of thyroid hormones. Thyroid hormones are essential for growth, but also and above all for the normal development of the brain during fetal life and childhood. In adulthood, they are primarily involved in regulating body temperature (thermoregulation), controlling metabolism (energy expenditure), fertility, intestinal transit, heart rate and mood. Hypothyroidism occurring in adulthood is most often acquired and has various causes (autoimmunity, thyroid surgery, medication, etc.). It does not fall into the category of rare endocrine diseases, unlike congenital hypothyroidism.The latter may be caused by an absent thyroid (agenesis), an abnormally formed thyroid (dysgenesis), or a defect in the synthesis of thyroid hormones resulting from a mutation in one of the key enzymes (proteins) involved in hormone production. They are most often detected very early, during the first days of life, through neonatal screening. This enables rapid and effective management, preventing the harmful effects of thyroid hormone deficiency on the child’s brain and musculoskeletal development. During pregnancy, the mother provides the fetus with thyroid hormones, thereby compensating for the defect in the fetal thyroid’s hormone synthesis. However, once born, the affected baby no longer benefits from its mother’s thyroid hormones and must therefore promptly receive oral hormone replacement therapy.Another category of rare congenital thyroid diseases consists of disorders of the metabolism, transport and action of thyroid hormones, including syndromes of resistance to thyroid hormones. These conditions are very rare (1/19,000–1/40,000 births) and are caused by genetic abnormalities affecting one of the thyroid hormone receptors (there are two types). Thyroid hormones are produced in sufficient quantities, but are unable to act optimally in tissues containing the mutated receptor (brain, liver, heart, muscle and bone). The severity and type of symptoms vary considerably depending on the mutation. For the most common forms of these rare disorders, which are also the least severe, diagnosis is most often made following so-called “discordant” thyroid function tests (with an unusual profile) performed during routine blood tests or as part of family screening after a known familial mutation has been identified.  Diagnosis and management Congenital hypothyroidism is screened for in newborns. A drop of blood is taken from the newborn’s heel between the 2nd and 5th day of life and placed on filter paper before being analysed. Parents are recalled for an endocrinology consultation if the screening test result is abnormal. Additional tests are performed to confirm the diagnosis (a follow-up blood test) and determine its cause (thyroid ultrasound and scintigraphy). Treatment consists of early replacement therapy with thyroid hormones, started in the first days of life. This treatment is simple, well tolerated and enables the child to develop normally. As with acquired hypothyroidism, the aims of continued follow-up into adulthood are to ensure proper metabolic function, fertility and an optimal quality of life in all areas (physical, psychosocial and professional).Regular clinical and biological follow-up is essential in order to adjust the doses as the child grows, as well as in response to changing needs in certain situations (weight fluctuations, interactions with other medicines, digestive absorption problems, fertility, pregnancy, etc.).Medical follow-up must continue throughout life. Providing patients and families with information and support is essential to ensure treatment adherence and long-term quality of life.In the most common cases of resistance to thyroid hormones, symptoms are mild and patients generally do not require specific treatment. However, this is a difficult diagnosis to make and requires the exclusion of other conditions through specific tests (including genetic analysis for confirmation), with a risk of diagnostic error that may lead to unnecessary thyroid surgery or drug treatment. Follow-up is also essential, as symptoms may evolve and require drug treatment. Care pathways File hypothyroidie_congenitale_.pdf File maladies_du_metabolisme_transport_et_action_des_hormones_thyroidiennes.pdf Transition to adulthood During adolescence, a gradual preparation for the transition to adult care is organised. This stage helps strengthen the young patient’s autonomy, ensure continuity of medical follow-up, and transfer all the necessary information to the specialised adult service. The transition is planned in collaboration with the patient, their family, and the paediatric and adult care teams. Focus / Search Patients are treated by a qualified adult endocrinologist. Hormone assays and genetic tests are carried out in a specialised laboratory. Genetic counselling is offered. An on-call service is available 24 hours a day. Our centre is actively involved in improving knowledge and care for patients with rare endocrine diseases.A local registry of cases of congenital hypothyroidism and thyroid hormone resistance has been established, and the number of new cases managed is continuously reported to the European ENDO-ERN registry. The aim is to optimise follow-up practices and compare care between different specialised centres. The team receives ongoing training, participates in congresses and seminars, initiates and collaborates on single-centre and multicentre studies, and publishes in the field of thyroid disorders. It also provides training and teaching for students and doctors in training. Our specialists
Congenital hypothyroidism
Health issues
Rare endocrine diseases
Department presentation The Adult Endocrinology Clinic provides diagnosis and follow-up for adult patients with an endocrine disorder, meaning a condition affecting the secretion of a hormone (excessive or insufficient secretion) and/or the gland that secretes it. The department therefore manages conditions affecting the thyroid, parathyroid glands, adrenal glands, gonads (ovaries and testicles), and pituitary gland.Since 2016, the Endocrinology Department of Erasme Hospital, together with the Queen Fabiola Children’s University Hospital (HUDERF) for paediatric care, has been part of the ENDO-ERN network (European Reference Network for Rare Endocrine Conditions), the European Reference Network for rare endocrine diseases.This network aims to improve access to high-quality care for patients with rare endocrine disorders. It supports clinical research and contributes to the creation of registries that list patients receiving follow-up for rare conditions, in order to promote knowledge-sharing and improve clinical practices.The management of rare endocrine diseases is multidisciplinary. Regular discussions are organised for complex cases with numerous specialists within our institution, as well as during virtual consultations with recognised European experts through the ENDO-ERN network or during international multidisciplinary consultation meetings (France).Some endocrine diseases begin at birth or during childhood and require lifelong treatment and follow-up. Transition consultations have been provided for many years in collaboration with our paediatric colleagues at HUDERF, to ensure the smoothest possible transition from paediatric to adult care.  What are rare congenital thyroid diseases? Rare congenital thyroid diseases are conditions that are most often present from birth and affect the functioning of the thyroid gland. In the majority of cases, they involve congenital hypothyroidism, i.e. insufficient production of thyroid hormones. Thyroid hormones are essential for growth, but also—and above all—for the normal development of the brain during fetal life and childhood. In adulthood, they are primarily involved in regulating body temperature (thermoregulation), controlling metabolism (energy expenditure), fertility, intestinal transit, heart rate and mood. Hypothyroidism occurring in adulthood is most often acquired and has various causes (autoimmunity, thyroid surgery, medication, etc.). It does not fall into the category of rare endocrine diseases, unlike congenital hypothyroidism.The latter may be caused by an absent thyroid (agenesis), an abnormally formed thyroid (dysgenesis), or a defect in the synthesis of thyroid hormones linked to a mutation in one of the key enzymes (proteins) involved in hormone production. They are most often detected very early, during the first days of life, through newborn screening. This enables rapid and effective management, helping to prevent the harmful effects of thyroid hormone deficiency on the child’s brain and musculoskeletal development. During pregnancy, the mother provides the fetus with thyroid hormones and thus compensates for the defect in hormone synthesis by the fetal thyroid. However, once born, the affected baby no longer benefits from its mother’s thyroid hormones and must therefore receive prompt oral hormone replacement therapy.Another category of rare congenital thyroid diseases comprises disorders of the metabolism, transport and action of thyroid hormones, including thyroid hormone resistance syndromes. These very rare conditions (1/19,000–1/40,000 births) are caused by genetic abnormalities affecting one of the thyroid hormone receptors (there are two types). Thyroid hormones are produced in sufficient quantities, but cannot act optimally in tissues containing the mutated receptor (brain, liver, heart, muscle and bones). The severity and type of symptoms vary considerably depending on the mutation. In the most common forms of these rare conditions, which are also the least severe, the diagnosis is most often made following so-called “discordant” thyroid function tests (with an unusual profile) performed during routine blood tests or as part of family screening in the context of a known familial mutation.   Diagnosis and management Congenital hypothyroidism is screened for in newborns. A drop of blood is taken from the newborn’s heel between the 2nd and 5th day of life and placed on filter paper before being analysed. The parents are recalled for an endocrinology consultation if the screening test result is abnormal. Additional tests are performed to confirm the diagnosis (a follow-up blood test) and determine its cause (thyroid ultrasound and scintigraphy). Management is based on early treatment with thyroid hormone replacement therapy, started during the first days of life. This treatment is simple, well tolerated and enables the child to develop normally. As with acquired hypothyroidism, the challenges when continuing follow-up into adulthood are to ensure proper metabolic function, fertility and optimal quality of life in all areas (physical, psychosocial and professional).Regular clinical and laboratory follow-up is essential in order to adjust the doses as the child grows, as well as according to changing needs in certain situations (weight fluctuations, interactions with other medicines, digestive absorption problems, fertility, pregnancy, etc.).Medical follow-up must continue lifelong. Providing patients and families with information and support is essential to ensure treatment adherence and long-term quality of life.In the most common cases of resistance to thyroid hormones, symptoms are mild and patients generally do not require specific treatment. However, this is a difficult diagnosis to make and requires the exclusion of other conditions through specific tests (including genetic analysis for confirmation), with a risk of misdiagnosis that could lead to unnecessary thyroid surgery or drug treatment. Follow-up is also essential, as symptoms may evolve and require drug treatment.  Care pathway File trajetdesoin.pdf Transition to adulthood During adolescence, a gradual preparation for the transition to adult care is organised. This step helps strengthen the young patient’s autonomy, ensure continuity of medical follow-up, and transfer all the necessary information to the specialised adult service. The transition is planned in collaboration with the patient, their family, and the paediatric and adult care teams. Focus: expertise Patients are treated by an accredited adult endocrinologist. Hormone assays and genetic tests are performed in a specialised laboratory. Genetic counselling is offered. An on-call service is available 24 hours a day. Our centre is actively committed to improving knowledge and care for patients with rare endocrine diseases.A local registry of cases of congenital hypothyroidism and thyroid hormone resistance has been established, and the number of new cases managed is continuously reported to the European ENDO-ERN registry. The aim is to optimise follow-up practices and compare patient management between different specialised centres. The team undertakes continuing education, participates in congresses and seminars, initiates and collaborates on single-centre and multicentre studies, and publishes work in the field of thyroid disease. It also provides training and teaching for students and doctors in training. Our specialists Associated department
Rare endocrine diseases
Rich page
Geriatrics Symposium
The must-attend event for anyone and all healthcare professionals interested in geriatric care and care pathways that support healthy ageing for older adults. Preliminary Programme 6:00 PM – Welcome and registration 6:30 PM – Keynote: Geriatrics – Helping People Continue Living What Matters MostDr Pierre Hanotier, Head of the Department of Geriatrics, H.U.B 6:40 PM – 7:00 PM | Flash Talks – One Expertise, One Message, Five Minutes 6:40 PM – Cardiogeriatrics: From Organ-Based Medicine to Person-Centred CareDr Véronique Lesage, Geriatrician specialised in cardiogeriatrics and palliative care, Erasmus Hospital, H.U.B 6:45 PM – Orthogeriatrics: The Care Model That Improves Outcomes for Older PatientsDr Laetitia Beernaert, Geriatrician specialised in orthogeriatrics, Erasmus Hospital, H.U.B 6:50 PM – Oncogeriatrics: When Age No Longer Determines TreatmentDr Julie Caillet, Geriatrician specialised in oncogeriatrics, Jules Bordet Institute, H.U.B and Dr Nathalie Compté, Geriatrician, CHU Helora 6:55 PM – Sexual Health: Pleasure Has No Expiry DateDr Nathan Franceschi, Geriatrician, Erasmus Hospital, H.U.B 7:00 PM – Geriatric Rehabilitation: Regaining Abilities, Preserving Life GoalsDr Anne Mergam, Geriatrician, Geriatric Rehabilitation Centre (GRC), Erasmus Hospital, H.U.B 7:10 PM – Healthy Aging Keynote: Supporting Health and Independence for as Long as Possible!Dr Pierre Hanotier 8:00 PM – Networking Dinner 9:30 PM – End of the Symposium Register Practical Information Date: Thursday, 12 November 2026Venue: Jules Bordet Institute, 90 Rue Meylemeersch, 1070 Brussels, Tagnon Auditorium (1st floor). DirectionsThis symposium is open to everyone: healthcare professionals, people interested in geriatric care, anyone wishing to learn more about healthy ageing, and general practitioners who would like to strengthen collaboration with geriatricians.Participation is free of charge, but registration is mandatory. Registration deadline: 6 November 2026.Participating physicians will receive accreditation points. Accreditation points will only be awarded to physicians who attend the symposium in its entirety.The symposium will be held in French. Contact With the support of Image
Rich page
Symposium on Interventional Radiology in Gynaecology
Interventional radiology in gynecology: minimally invasive innovations to preserve health and fertility Interventional radiology is playing an increasingly important role in the management of gynecological conditions. Thanks to image-guided minimally invasive techniques, it provides alternatives or complements to conventional treatments, with potential benefits including organ preservation, reduced complications and improved patients’ quality of life.This symposium will provide a multidisciplinary overview of the latest advances in interventional radiology applied to gynecology. Gynecologists, interventional radiologists and specialists involved in the management of pelvic pathologies will come together to discuss current indications, clinical outcomes and future perspectives of these approaches.Therapeutic innovations at the heart of gynecological careTargeted embolization: a conservative approach for uterine conditionsArterial embolization allows precise targeting of the blood supply of certain gynecological lesions, offering an alternative or complement to conventional treatments while preserving the uterus.This session will address in particular:Uterine fibroids (fibromyomas): indications, clinical outcomes and the role of embolization within today’s therapeutic options.Pelvic adenomyosis: new perspectives for managing a condition often responsible for chronic pain and menstrual disorders.Thermal ablation: new minimally invasive strategies for deep endometriosisThermal ablation opens up new perspectives in the management of certain deep endometriosis lesions through a targeted approach that limits the impact on surrounding tissues. This session will present the indications, available outcomes and the role of this technique within a personalized therapeutic strategy.Pelvic vascular conditions: diagnosing and treating differentlySome chronic pelvic pain conditions may be related to vascular abnormalities. Experts will present recent advances in:Pelvic varices embolization: a targeted approach to treating pelvic congestion syndrome in selected patients.Management of varicoceles: with particular focus on indications and outcomes.Restoring fertility: the potential of selective tubal recanalizationIn certain cases of proximal tubal obstruction, selective tubal recanalization is a minimally invasive approach that may restore tubal patency. This session will explore its role within infertility care pathways and its integration into individualized patient management.A comprehensive reflection on interventional radiology in gynecologyCross-cutting challenges: responsible practice of interventional radiology in gynecologyBeyond technical innovations, the development of these approaches raises essential questions:What ethical challenges will accompany the evolution of these practices?How can economic considerations be integrated into therapeutic decision-making?How can radiation protection for patients and healthcare professionals be optimized?A comprehensive reflection is essential to ensure innovative, responsible and patient-centered medicine.A symposium to strengthen collaboration between specialistsThis symposium is aimed at gynecologists wishing to deepen their knowledge of available interventional techniques in gynecology and better identify situations in which these approaches can be offered to their patients.It provides an opportunity to exchange with specialists in interventional radiology and gynecology through clinical cases, practical experiences and discussions on future developments.Practical informationDate: Saturday, 21 November 2026Time: 08:00 AM to 03:00 PMLocation: Museum of Medicine, Erasme Campus – Place Facultaire. Route de Lennik 808, 1070 Anderlecht. AccessTarget audience: gynecologists, interventional radiologists and specialists involved in the management of pelvic pathologiesAccredited symposium organized under the direction of Dr Salvatore Murgo and Dr Arnaud Bourguignon.Free registration required (registration deadline: 14/11/2026)Contact: Interventional Radiology Angiography Coordination, coordination [dot] RI [at] hubruxelles [dot] be Registration
Article
Unable to attend? Cancel your appointment in time to avoid charges!
Appointments that are neither attended nor cancelled are a major cause of delays in our hospitals. If you are unable to keep your appointment, please let us know as soon as possible.  Any appointment that is missed and not cancelled at least 48 hours before the scheduled time will incur a fee:30 euros for a consultation or a standard scintigraphy scan100 euros for an MRI, an X-ray, a CT scan or a PET-CT scan€200 for a procedureThere are several ways to cancel an appointment:Through the MyHUB app, if you originally booked your appointment via the appUsing the cancellation forms available on our websiteOr by calling 02 555 55 55 and following the menu options until you reach the relevant department. 
Information
Uncancelled appointments
Appointments that are neither attended nor cancelled are a major cause of delays in our hospitals. If you are unable to keep your appointment, please let us know as soon as possible. Any appointment that is missed and not cancelled at least 48 hours before the scheduled time will incur a fee: 30€ for a consultation or a standard scintigraphy scan100€ for an MRI, an X-ray, a CT scan or a PET-CT scan200€ for a procedure There are several ways to cancel an appointment: Through the MyHUB app, if you originally booked your appointment via the appUsing the cancellation forms available on our websiteOr by calling 02 555 55 55 and following the menu options until you reach the relevant department.  You can cancel your appointment up tu 48 hours before with no fees incurred
Health issues
Eosinophilic oesophagitis
What is eosinophilic oesophagitis? Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory disease of the esophagus that affects children and young adults and manifests as difficulty swallowing (dysphagia), chest pain, and sometimes food becoming lodged in the esophagus. In children, esophagitis often manifests as vomiting, abdominal/chest pain, and refusal to eat. Patients often adapt their diet, avoid certain foods (bread, meat, rice), and eat more slowly. Chronic inflammation makes the esophagus stiffer, which can lead to narrowing (strictures). Therefore, to prevent this progression, long-term follow-up and maintenance treatment are indicated. First consultation Gastroenterology consultation, recording of symptoms, recording of any allergies and atopic diseases, and assessment of nutritional status. Diagnosis The diagnosis of EoE is based on the triad of symptoms of oesophageal dysfunction (particularly dysphagia), eosinophilic infiltration on oesophageal biopsies, and exclusion of other causes of oesophageal eosinophilia.Investigations Gastroscopy (OGD) with biopsies: Essential examination that may reveal rings, furrows, a trachealised appearance, white exudates (microabscesses), or a fragile mucosa. At least 6 oesophageal biopsies (proximal and distal) are essential.Histology: Confirmation of the presence of at least 15 eosinophils per high-power field.Full blood count (FBC): To look for blood eosinophilia, which is often moderate. Allergy assessment: Not indicated as a first-line investigation in adult patients; skin tests (prick tests) or specific IgE measurements, often targeting milk, wheat, eggs or soya, are sometimes performed, although their sensitivity is limited.Barium oesophagram (TOGD or OED X-ray): Performed in cases of significant stenosis (narrowing) to map the lesions before endoscopic dilatation. Treatments Treatment of EoE aims to reduce inflammation, relieve symptoms (dysphagia) and prevent fibrosis. First-line treatment is based on proton pump inhibitors (PPIs), topical corticosteroids (swallowed), or elimination diets, often continued long term. PPIs: Often the first step in reducing inflammation, although their exact mechanism in EoE is not strictly related to reflux (intrinsic anti-inflammatory effect). Topical/local corticosteroids: Orodispersible budesonide is highly effective in treating inflammation and relieving symptoms; it is reimbursed in Belgium in cases of resistance to PPIs.Elimination diets: Removal of the most frequently implicated allergenic foods (milk, wheat, soya, eggs, tree nuts, fish and shellfish), ideally under dietary supervision. These diets are difficult to follow in adults and affect quality of life. For these reasons, an elimination diet excluding one or two allergens (milk, or milk and wheat) may be offered as first-line treatment.Biological therapies: New biological medicines targeting inflammation, such as dupilumab, are used when treatment with PPIs and budesonide fails. Dupilumab is reimbursed in Belgium for this indication.Oesophageal dilatation: Performed endoscopically in cases of significant narrowing (stricture) of the oesophagus. Follow-up Eosinophilic oesophagitis is a chronic disease requiring long-term medical follow-up to prevent complications, particularly fibrosis or strictures. Follow-up, supervised by a gastroenterologist, combines symptom assessment, endoscopies with biopsies, and management of treatments (PPIs, corticosteroids, biologic medication, diet).Regular medical follow-up: An annual consultation, or even one every two years, is recommended to assess treatment adherence and symptoms.Endoscopic monitoring: This is necessary because symptoms alone are not sufficient to assess disease activity. A follow-up endoscopy is necessary if treatment is modified (dose reduction or discontinuation of a medication) to confirm histological remission (a decrease in the number of eosinophils to < 15 per field).Maintenance treatments: prescribed to prevent recurrences. Most patients relapse when treatment is stopped, underscoring the importance of chronic management. Multidisciplinary approach: Follow-up often involves an allergist and a dietitian, particularly if an elimination diet is undertaken (milk, wheat, etc.).Monitoring for complications: Repeated endoscopies make it possible to monitor the development of strictures (narrowing of the oesophagus).  Transition to adulthood The transition of patients treated and followed in paediatrics takes place during a gastroenterology consultation, in order to provide the necessary follow-up in adulthood. Our specialists Associated department
Eosinophilic oesophagitis
Information
What to remember before coming to the hospital?
On the day of your consultation please go to one of the registration terminals in the central hall 20 minutes before your appointment.  Documents to bring with you Your identity documents Any document attesting to your rights to receive care (“BIM”, “réquisitoire” to cover medical expenses.) The results of or prescription for any examinations if applicable Documents to bring with you
Health issues
Interstitial and Diffuse Pneumonias Clinic
What are interstitial pneumonias? Diffuse interstitial pneumonias are a group of relatively rare lung diseases. They are disorders of the lung parenchyma (that is, of the lung itself) with a varying degree of inflammation and fibrosis resulting in a sometimes severe respiratory insufficiency.  The principal pathologies covered by this term are •    Idiopathic pulmonary fibrosis •    Sarcoidosis •    Non-specific interstitial pneumonia •    Cryptogenic organising pneumonia •    Lung disorders secondary to autoimmune diseases (connective tissue disease and vasculitis)  •    Hypersensitivity pneumonitis (farmer‘s lung, bird fancier’s lung •    Some pneumonias of occupational origin (exposure to asbestos or to mineral or metal dust) or drug induced Idiopathic pulmonary fibrosis (IPF) Idiopathic pulmonary fibrosis (IPF) is the most common disease of this group, together with sarcoidosis. The annual incidence is estimated at 10 new cases for 100,000 persons per year and this figure seems to be rising. In IPF the lung is progressively destroyed and replaced by scar tissue. This results in an irreversible and progressive respiratory insufficiency.  Causes and risk factors Its etiology is unknown but smoking, pollution, exposure to certain viruses and the presence of gastroesophageal reflux are risk factors. There are also family forms in which gene mutations have been clearly identified.  IPF affects more men than women and is generally diagnosed at around the age of 60.  Diagnosis and treatment These diseases are rare and therefore demand particular expertise. The diagnosis is complex and requires a multidisciplinary discussion.  In the case of idiopathic pulmonary fibrosis there are two possible treatments: with Esbriet or Ofev. These do not cure the diseases but do make it possible to slow its progress.  If the patient shows no contraindications a lung transplant must be envisaged. In this particular case we work closely together with the lung transplant team. Multidisciplinary meetings are held regularly to discuss complex cases and we have a clinical research unit that permits access to an advanced research programme in this field and patients are invited to participate in international trials to test new treatments.  The Erasmus Hospital is a member of the European experts network in the field of diffuse interstitial pneumonia (ERN lung). We are active in the field of clinical research by providing the opportunity to participate in research protocols and clinical trials.  Finally, we support and participate actively in activities organised by patients’ associations, in particular the   Association Belge Francophone contre la Fibrose Pulmonaire (ABFFP). Useful documents Informations destinées aux patient(e)s Brochure : thérapie par Esbriet (pirfénidone) Brochure : Fibrose Pulmonaire Idiopathique (FPI) Brochure : traitement de votre Fibrose Pulmonaire Idiopathique (FPI) avec OFEV® File information_patient_pid_hub_v3.pdf File 1.2.d_interventions.pdf Requests for opinion Téléchargez le document de demande d'avis de la part du médecin traitant ou spécialiste à destination de la Clinique des pneumopathies interstitielles diffuses. Demande d'avis Multidisciplinary team Découvrez l'équipe multidisciplinaire de la Clinique de Pneumopathies interstitielles et diffuses. Organisation chart Our specialists
Interstitial and Diffuse Pneumonias Clinic
Article
Discover all H.U.B videos on YouTube!
Care pathways, patient testimonials and health information: find all the videos on the H.U.B’s YouTube channel! Image Care pathways, testimonials, research, training and health information: find all H.U.B videos in one place! Brussels University Hospital offers a wide range of audiovisual content on YouTube (@hopitaluniversitairebruxelles). Content to help you better understand health, the hospital and its areas of expertise The channel offers several types of content: Care pathways and testimonials: discover patients’ experiences and the care provided by our teams. Hospital life and professions: meet the professionals who make the hospital come alive every day. Research and innovation: learn about the scientific projects and medical advances to which our teams contribute. Training and seminars: find content intended for healthcare professionals. Health information: access reliable explanations about diseases, their diagnosis, prevention and treatment. HOP'Voices: listen to podcast episodes and discover the topics that inspire our teams. One shared channel, improved access to health information By bringing this content together, H.U.B aims to make it easier for its various audiences to discover and share: healthcare professionals, patients, relatives and the general public. Subscribe to the channel now (@hopitaluniversitairebruxelles) and share the videos you find interesting and useful for yourself or your loved ones. Every share can help make health information accessible to everyone. Discover the H.U.B channel on YouTube!